The global multiomics market size was estimated at USD 2.53 billion in 2023 and is projected to hit around USD 10.48 billion by 2033, growing at a CAGR of 15.3% during the forecast period from 2024 to 2033.
Key Takeaways:
Multiomics Market Growth
The growth of the market can be attributed to the increasing demand for single-cell multiomics and advancements in omics technologies. Moreover, the categories such as genomics, proteomics, metabolomics, and transcriptomics are gaining momentum for healthcare purposes. The COVID-19 pandemic had a positive impact on the industry. The multiomics approaches have been considered for COVID-19 diagnosis and insights. Various studies and research were conducted to understand the multiomics role in the COVID-19 diagnosis.
For instance, according to the study published by the MDPI in September 2021, multiomics technology can provide significant new insights to understand COVID-19. In addition, large datasets generated by the high-throughput multiomics approaches possess much information that can help in therapeutic developments.
Researchers have undertaken numerous efforts to develop platforms and multiomics databases to assist in COVID-19 data analysis and research. For instance, in August 2021, a new multidimensional dataset, COVIDome, was released to the public for COVID-19 multiomics research and data analysis. This dataset was helpful to collaborate in real-time and transmit data for the clinical management of COVID-19. Such developments have driven the market growth during the COVID-19 pandemic.
The industry is expected to witness significant growth due to increasing demand for single-cell multiomics. Companies are developing novel single-cell platforms. For instance, in February 2023, BD (Becton, Dickinson, and Company) introduced a single-cell multiomics platform, BD Rhapsody HT Xpress System, to help in scientific discovery in various fields, including genetic disease research, immunology, cancer and chronic disorder research.
The increasing interest among researchers in the field of single-cell genomics is also expected to boost the market demand. According to the research published by the National Library of Medicine in March 2023, single-cell genomics has wide applications in the field of cardiovascular disorder research. It can be utilized in heart development, Myocardial Infarction (MI), Cardiac Ischemia-Reperfusion (I/R) Injury, atherosclerosis, atrial fibrillation, cardiac hypertrophy, and heart failure.
Single-cell genomics can facilitate novel treatments for cardiovascular diseases (CVDs). Furthermore, the prevalence of CVDs is increasing significantly. According to the American Heart Association, around 19.1 million people across the world lost their lives due to CVDs in 2020. Thus, with the increasing CVDs, the demand for single-cell genomics is also expected to increase significantly, driving market growth.
Multiomics Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 2.91 Billion |
| Market Size by 2033 | USD 10.48 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 15.3% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product & service, type, platform, application, end-use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | BD; Thermo Fisher Scientific Inc.; Illumina, Inc; Danaher; PerkinElmer Inc.; Shimadzu Corporation; Bruker; QIAGEN; Agilent Technologies, Inc.; BGI |
Product & Service Insights
The product segment accounted for the largest market share of 61.19% in 2023. The products are further segmented into instruments, consumables, and software. The growing developments and increasing product launches are expected to drive the segment growth. Companies are undergoing partnerships to develop novel platforms and instruments for multiomic research and analysis. For instance, in April 2023, Bio-Techne collaborated with Lunaphore to develop a fully automated spatial multiomics solution. Such developments are anticipated to drive the segment’s growth over the forecast period.
The service segment is projected to grow at the fastest CAGR of 17.4% from 2023 to 2033. Due to the increasing demand, participants are offering numerous services focusing on multiomics. For instance, in September 2023, Psomagen, a multiomics contract research organization, introduced Spatial Biology services. This service integrates various omics platforms, including transcriptomics, genomics, and proteomics. Thus, increasing service offerings are anticipated to drive the segment growth in the coming years.
Type Insights
Based on type, the multiomics market is segmented into single-cell multiomics and bulk multiomics. The bulk multiomics segment dominated the type segment in 2023. Typically, bulk multiomics is essential for systematically explaining disorder pathogenesis and different phenotypes at the individual level. The various advantages of bulk multiomics can be attributed to the segment's dominance. These advantages include the simple experimental process and affordable large-scale sample dissection. Moreover, bulk multiomics approaches do not need living cells.
The single-cell multiomics segment is anticipated to witness the fastest CAGR of 17.9% during 2023-2033. The higher growth rate is attributed to the increasing demand for single-cell multiomics to understand complex biological systems. In addition, the participants are focusing on these types of products. For instance, in October 2020, Mission Bio, Inc. introduced a complete Tapestri Single-cell Multiomics Solution to develop precision cancer therapies. This solution combines two assays in a single platform and offers deeper insight into therapy relapse and resistance. Such initiatives and product launches are anticipated to boost the segment growth over the forecast period.
Platform Insights
The genomics segment dominated the market with a revenue share of 41.16% in 2023. There has been development of several advanced products in the genomics industry. Moreover, companies are increasing their offerings in this segment, which further propels the segment's growth. For instance, in May 2023, Google Cloud introduced an AI-powered Multiomics Suite. This offering can help in the interpretation of genomic data and in designing precision treatments. Thus, launches focusing on genomic data interpretation are expected to drive segment growth over the forecast period.
The metabolomics segment is projected to exhibit the fastest growth with a CAGR of 17.6% from 2023 to 2033. The increasing prevalence of cancer across the world and the rising number of studies focusing on multiomics approaches for cancer research are expected to drive the segment growth. According to the study published in February 2018, metabolomics plays an essential role in prognosis research of pancreatic cancer.
Application Insights
The cell biology segment dominated the market with a revenue share of 38.8% in 2023. Integrating multiomics approaches is revolutionizing the understanding of cellular biology within the contexts of both health and disease. Moreover, numerous solutions are available to understand cell biology. For instance, in February 2023, BioSkryb Genomics introduced two platforms that can enable single-cell multiomic analysis. Such products can help in the understanding of cell biology using multiomic platforms.
The oncology segment is projected to exhibit the fastest growth with a CAGR of 18.0% from 2023 to 2033. The rising incidences of cancer and the growing utility of multiomics for cancer are anticipated to drive the segment growth. Researchers and companies are undertaking numerous efforts to help cancer patients using multi-omic approaches. For instance, in September 2022, Freenome, a biotech company, launched the Sanderson Study, combining its multiomics platform with real-world data to identify multiple cancers.
End-use Insights
The academic and research institutes segment captured the largest market share of 52.7% in 2023. The increasing studies and research focusing on multiomics approaches, including genomics, proteomics, metabolomics, and transcriptomics, are anticipated to drive segment growth over the forecast period. Moreover, this segment is receiving funding and investment for conducting research in this field. For instance, in September 2023, the National Institutes of Health established the Multiomics for Health and Disease Consortium and provided USD 50.3 million for multiomics research. This consortium includes professionals from various universities, including the University of California, Columbia University, and Washington University.
The pharmaceutical and biotechnology companies segment is projected to register the fastest CAGR of 17.5% from 2024 to 2033, owing to the potential benefits that multiomics technologies offer in drug discovery, development, and personalized medicine. Thus, the adoption of multiomics by biotechnology and pharmaceutical companies is anticipated to increase significantly to accelerate drug discovery and development.
Regional Insights
North America dominated the market with a share of 49.45% in 2023, and the region is projected to register the fastest growth throughout the forecast period. The presence of key players in the region supports the highest revenue share. Moreover, companies are undertaking numerous efforts to strengthen their presence is also fueling regional industry. For instance, in February 2023, Tempus, the U.S.-based company, collaborated with Actuate Therapeutics to help discover and further validate biomarker profiles in patients who have cancer. Tempus is using the multiomics approach in this project to improve research and increase novel scientific insights. Such strategies are driving regional expansion.
Asia Pacific is expected to grow at a significant CAGR of 17.8% from 2024 to 2033. The growth of the region can be attributed to various factors, including the rising prevalence of chronic conditions, the widespread product adoption for analysis and visualization, and technological advances coupled with rising research and development (R&D) investments. Moreover, various companies are introducing studies based on multiomics. For instance, in May 2021, using a multiomics approach, Burning Rock Biotech Limited introduced the PRESCIENT study, the first blood-based, pan-cancer early-detection study in China. Thus, the increasing focus of players in the Asia Pacific region also highlights the regional market's growth over the forecast period.
Some of the prominent players in the Multiomics Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Multiomics market.
By Product & Service
By Type
Single-cell Multiomics
Bulk Multiomics
By Platform
By Application
By End-use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Information Analysis
1.2.2. Market Platform & Data Visualization
1.2.3. Data Validation & Publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Platform & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing demand for single cell omics
3.2.1.2. Advancements in omics technology and decreasing costs of omics technologies
3.2.1.3. Increasing investments and funding from private and public players
3.2.2. Market Restraint Analysis
3.2.2.1. Challenges in multiomics data integration and data complexity
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product & Service Business Analysis
4.1. Multiomics Market: Product & Service Movement Analysis
4.2. Products
4.2.1. Products Market, 2021 - 2033
4.2.2. Instruments
4.2.2.1. Instruments Market, 2021 - 2033
4.2.3. Consumables
4.2.3.1. Consumables Market, 2021 - 2033
4.2.4. Software
4.2.4.1. Software Market, 2021 - 2033
4.3. Services
4.3.1. Services Market, 2021 - 2033
Chapter 5. Type Business Analysis
5.1. Multiomics Market: Type Movement Analysis
5.2. Single- Cell Multiomics
5.2.1. Single- Cell Multiomics Market, 2021 - 2033
5.3. Bulk Multiomics
5.3.1. Bulk Multiomics Market, 2021 - 2033
Chapter 6. Platform Business Analysis
6.1. Multiomics Market: Platform Movement Analysis
6.2. Genomics
6.2.1. Genomics Market, 2021 - 2033
6.3. Transcriptomics
6.3.1. Transcriptomics Market, 2021 - 2033
6.4. Proteomics
6.4.1. Proteomics Market, 2021 - 2033
6.5. Metabolomics
6.5.1. Metabolomics Market, 2021 - 2033
6.6. Integrated Omics Platforms
6.6.1. Integrated Omics Platforms Market, 2021 - 2033
Chapter 7. Application Business Analysis
7.1. Multiomics Market: Application Movement Analysis
7.2. Cell Biology
7.2.1. Cell Biology Market, 2021 - 2033
7.3. Oncology
7.3.1. Oncology Market, 2021 - 2033
7.4. Neurology
7.4.1. Neurology Market, 2021 - 2033
7.5. Immunology
7.5.1. Immunology Market, 2021 - 2033
Chapter 8. End-use Business Analysis
8.1. Multiomics Market: End-use Movement Analysis
8.2. Academic and Research Institutes
8.2.1. Academic and Research Institutes Market, 2021 - 2033
8.3. Pharmaceutical & Biotechnology Companies
8.3.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033
8.4. Others
8.4.1. Others Market, 2021 - 2033
Chapter 9. Regional Business Analysis
9.1. Multiomics Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. North America Multiomics Market, 2021 - 2033
9.2.2. U.S.
9.2.2.1. Key Country Dynamics
9.2.2.2. Target Disease Prevalence
9.2.2.3. Competitive Scenario
9.2.2.4. U.S. Multiomics Market, 2021 - 2033
9.2.3. Canada
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Canada Multiomics Market, 2021 - 2033
9.3. Europe
9.3.1. Europe Multiomics Market, 2021 - 2033
9.3.2. UK
9.3.2.1. Key Country Dynamics
9.3.2.2. Target Disease Prevalence
9.3.2.3. Competitive Scenario
9.3.2.4. UK Multiomics Market, 2021 - 2033
9.3.3. Germany
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Germany Multiomics Market, 2021 - 2033
9.3.4. France
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. France Multiomics Market, 2021 - 2033
9.3.5. Italy
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Italy Multiomics Market, 2021 - 2033
9.3.6. Spain
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Spain Multiomics Market, 2021 - 2033
9.3.7. Denmark
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Denmark Multiomics Market, 2021 - 2033
9.3.8. Sweden
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Sweden Multiomics Market, 2021 - 2033
9.3.9. Norway
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Norway Multiomics Market, 2021 - 2033
9.4. Asia Pacific
9.4.1. Asia Pacific Multiomics Market, 2021 - 2033
9.4.2. Japan
9.4.2.1. Key Country Dynamics
9.4.2.2. Target Disease Prevalence
9.4.2.3. Competitive Scenario
9.4.2.4. Japan Multiomics Market, 2021 - 2033
9.4.3. China
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. China Multiomics Market, 2021 - 2033
9.4.4. India
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. India Multiomics Market, 2021 - 2033
9.4.5. Australia
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Australia Multiomics Market, 2021 - 2033
9.4.6. Thailand
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Thailand Multiomics Market, 2021 - 2033
9.4.7. South Korea
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. South Korea Multiomics Market, 2021 - 2033
9.5. Latin America
9.5.1. Latin America Multiomics Market, 2021 - 2033
9.5.2. Brazil
9.5.2.1. Key Country Dynamics
9.5.2.2. Target Disease Prevalence
9.5.2.3. Competitive Scenario
9.5.2.4. Brazil Multiomics Market, 2021 - 2033
9.5.3. Mexico
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Mexico Multiomics Market, 2021 - 2033
9.5.4. Argentina
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Argentina Multiomics Market, 2021 - 2033
9.6. MEA
9.6.1. MEA Multiomics Market, 2021 - 2033
9.6.2. South Africa
9.6.2.1. Key Country Dynamics
9.6.2.2. Target Disease Prevalence
9.6.2.3. Competitive Scenario
9.6.2.4. South Africa Multiomics Market, 2021 - 2033
9.6.3. Saudi Arabia
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Saudi Arabia Multiomics Market, 2021 - 2033
9.6.4. UAE
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. UAE Multiomics Market, 2021 - 2033
9.6.5. Kuwait
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Kuwait Multiomics Market, 2021 - 2033
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2022
10.4. Company Profiles/Listing
10.4.1. BD
10.4.1.1. Overview
10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Thermo Fisher Scientific, Inc,
10.4.2.1. Overview
10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Illumina
10.4.3.1. Overview
10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Danaher
10.4.4.1. Overview
10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. PerkinElmer
10.4.5.1. Overview
10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Shimadzu Corporation
10.4.6.1. Overview
10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Bruker
10.4.7.1. Overview
10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. QIAGEN
10.4.8.1. Overview
10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Agilent Technologies
10.4.9.1. Overview
10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. BGI
10.4.10.1. Overview
10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers